New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 17, 2014
05:34 EDTGWPHGW Pharmaceuticals provides update on cannabinoid pipeline
GW Pharmaceuticals provided an update on the company's cannabinoid pipeline. GW has completed a Phase 1 clinical trial of GWP42006 to treat epilepsy. CBDV was well tolerated even at the highest tested dose and no significant side effects were observed. There were no serious or severe adverse events, nor any withdrawals due to adverse events, and all mild adverse events resolved on treatment. CBDV has shown the ability to treat seizures in pre-clinical models of epilepsy with significantly fewer side effects than currently approved anti-epileptic drugs1. CBDV also appears to employ a different mechanism of action to currently available anti-epileptic treatments. GW expects to commence a Phase 2 study of CBDV in patients with epilepsy later in 2014, using the doses identified as appropriate in this Phase 1 study. GW also announced that the Intellectual Property Office in the United Kingdom has granted a patent for the use of CBDV in the treatment of epilepsy, patent number GB2479153B. This same patent is currently in prosecution with the USPTO. GW has commenced a 12-week randomized, double blind, placebo controlled Phase 2b study of GWP42004 to treat Type 2 diabetes. The primary objective of this study is to compare the change in glycemic control in participants with Type 2 diabetes when treated with one of three doses of GWP42004 or placebo as add-on therapy to metformin with the primary endpoint being change from baseline to the end of treatment in mean glycosylated haemoglobin A1c level. The safety and tolerability of GWP42004 compared with placebo will also be assessed. This study is expected to enroll approximately 200 patients with an estimated completion date of the second half of 2015. GW has commenced a Phase 2a trial using GWP42003 to treat schizophrenia. GWP42003 has shown notable anti-psychotic effects in accepted pre-clinical models of schizophrenia and importantly has also demonstrated the ability to reduce the characteristic movement disorders induced by currently available anti-psychotic agents. The mechanism of GWP42003 does not appear to rely on the D2 receptor augmentation of standard antipsychotics and therefore has the potential to offer a novel treatment option in this therapeutic area.
News For GWPH From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 14, 2014
18:20 EDTGWPHOn The Fly: After Hours Movers
Subscribe for More Information
17:26 EDTGWPHGW Pharmaceuticals CEO says market for Epidiolex may be expanded over time
Subscribe for More Information
14:55 EDTGWPHGW Pharma analyst day positive, reason for sell-off unclear, says Piper Jaffray
Subscribe for More Information
08:07 EDTGWPHGW Pharmaceuticals data should 'silence the doubters,' says Piper Jaffray
Subscribe for More Information
07:15 EDTGWPHGW Pharmaceuticals says Epidiolex physician reports show signals of efficacy
Subscribe for More Information
07:11 EDTGWPHGW Pharmaceuticals announces preliminary topline results of Phase 2a trial
Subscribe for More Information
06:38 EDTGWPHGW Pharmaceuticals to host research and development day
Subscribe for More Information
October 8, 2014
11:23 EDTGWPHGW Pharmaceuticals slides after U.K. body recommends against use of Sativex
Subscribe for More Information
10:24 EDTGWPHGW Pharmaceuticals weakness on NICE guidance 'irrational,' says Piper Jaffray
Subscribe for More Information
10:04 EDTGWPHNICE guidance does not recommend use of Sativex in MS care
In an update to its original 2003 guideline, the U.K.'s National Institute for Health and Care Excellence has set out how people with multiple sclerosis, or MS, can receive better care. In the update, NICE recommends that people with suspected MS should be referred to a consultant neurologist. MS should not be diagnosed on the basis of MRI findings alone and only a consultant neurologist should make the diagnosis of MS. The guidance does not recommend the use of the cannabinoid drug Sativex, manufactured by GW Pharmaceuticals (GWPH), or fampridine as they provide only a modest benefit at a significant cost to the NHS, NICE stated. Shares of GW Pharmaceuticals are down 7% in early trading following the publication of NICE's new guidelines.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use